Focal therapy is a treatment for prostate cancer that destroys only the tumor itself, leaving the rest of the prostate and surrounding structures intact. Think of it as the difference between removing an entire organ and surgically targeting just the problem area. By sparing the nerves, muscles, and tissues responsible for urinary and sexual function, focal therapy aims to control cancer while avoiding the significant side effects that come with removing or radiating the whole gland. It sits in a middle ground between active surveillance (monitoring without treatment) and radical approaches like full prostatectomy or whole-gland radiation.
How Focal Therapy Works
Rather than one single technique, focal therapy is an umbrella term for several energy-based technologies that destroy cancerous tissue in different ways. The most widely studied options include high-intensity focused ultrasound (HIFU), which uses concentrated sound waves to heat and destroy tissue; cryotherapy, which freezes it; irreversible electroporation, which uses short electrical pulses to rupture cancer cell membranes; and focal laser ablation, which uses targeted light energy. Each approach enters the body through the rectum or perineum (the area between the scrotum and rectum), guided by real-time imaging to pinpoint the tumor.
The procedure is typically performed as a one-to-two-hour outpatient visit under general anesthesia. A catheter is placed temporarily, and once it’s removed a few days later, most patients can return to normal activities, including sexual activity. Compared to radical surgery, which often requires weeks of recovery and carries lasting effects on bladder and sexual function, the recovery timeline is dramatically shorter.
A large systematic review covering 49 study groups treated between 2008 and 2024 found no clinically significant difference in cancer detection on follow-up biopsies between cryotherapy, HIFU, and irreversible electroporation. All three showed good short-to-intermediate-term results for both cancer control and quality of life.
Who Is a Candidate
Focal therapy works best for a specific profile: localized prostate cancer that hasn’t spread beyond the gland, ideally concentrated in one area rather than scattered throughout the prostate. Multiple expert consensus panels have converged on similar criteria, though the details vary slightly.
The ideal candidate has intermediate-risk cancer with a Gleason score of 3+4 (sometimes 4+3 is acceptable), a PSA level under 10 (and generally under 20), clinical stage T2c or lower with no signs of spread to lymph nodes or bones, and a life expectancy of at least 10 years. On MRI, the cancer focus should be relatively small, generally under 1.5 milliliters, and occupy no more than about 20% of the prostate. There should be no evidence of cancer extending beyond the prostate capsule or into the seminal vesicles.
Several factors can complicate candidacy. Tumors located at the apex (the bottom tip of the prostate) or in the anterior (front) portion can be technically difficult to reach with current tools. Prior radiation to the pelvis rules out most patients. For HIFU specifically, the prostate should generally be under 40 to 50 milliliters in volume. Previous prostate surgery or significant urinary symptoms don’t automatically disqualify someone, but they warrant careful discussion about risks.
Side Effects and Quality of Life
The strongest argument for focal therapy is what it preserves. Pad-free urinary continence rates range from 95% to 100% across multiple prospective studies. Urinary incontinence of any kind occurs in only 0% to 5% of patients, and when it does happen, recovery typically takes just a few weeks. For comparison, even with nerve-sparing radical prostatectomy, some degree of incontinence affects a much larger proportion of men and can persist for months.
Sexual function is more variable. Across systematic reviews, 54% to 100% of patients maintained erections sufficient for intercourse after focal therapy, with or without medication. The wide range reflects differences in baseline function before treatment and how much tissue was destroyed. Studies of focal cryotherapy specifically reported erectile function preservation in 68% to 93% of patients, while focal HIFU showed impotence rates of roughly 15%. The closer the ablation zone is to the nerve bundles that run along each side of the prostate, the higher the risk to sexual function.
Serious complications like rectal injury or fistula formation are rare. Most studies report no cases of rectal pain, perineal discomfort, or worsened urinary symptoms beyond the initial recovery period.
The Monitoring Plan Afterward
Because focal therapy leaves prostate tissue in place, follow-up is more involved than after radical surgery. The monitoring period should extend at least five years, and the schedule is fairly structured.
PSA blood tests start three months after treatment, then continue every three months through the first year and every six months after that. Imaging (typically MRI) is recommended at six months, one year, and then annually through five years. A thorough biopsy is performed at the one-year mark, combining a standard 12-core sampling of the whole prostate with 4 to 6 targeted cores of the treated area and any suspicious spots on imaging. After that first-year biopsy, further biopsies of both the treated and untreated areas are only performed if imaging raises concern.
One challenge unique to focal therapy is interpreting PSA results. Because healthy prostate tissue remains, PSA levels will still be detectable and can rise for reasons unrelated to cancer recurrence. This makes PSA less straightforward as a tracking tool than it is after complete gland removal, where any detectable PSA signals a problem.
Limitations and Uncertainties
Prostate cancer is frequently multifocal, meaning small deposits of cancer cells can exist in areas that look clean on imaging. This is the core tension with focal therapy: by treating only the visible tumor, there’s a risk of leaving behind disease that could progress. Improvements in MRI and targeted biopsy techniques have made tumor mapping more accurate, but no imaging method catches every focus of cancer.
If cancer does recur or persist after focal therapy, retreatment is possible. Patients can undergo a second round of focal therapy or escalate to radical surgery or radiation. This flexibility is one of the approach’s advantages, but it also means some patients end up receiving two treatments instead of one definitive intervention.
The biggest gap in evidence is long-term data. Most studies report outcomes over three to five years, and the results are encouraging. But prostate cancer often progresses slowly over 10 to 15 years, and there are no large randomized trials directly comparing focal therapy to surgery or radiation over that timeframe.
What Major Guidelines Say
Despite growing clinical use, focal therapy is not yet considered standard of care by the major urological organizations. The European Association of Urology recommends offering focal therapy only within a clinical trial or well-designed prospective study. The American Urological Association advises clinicians to inform patients that focal therapy and HIFU lack comparative outcome evidence and should be performed in a trial context. The National Comprehensive Cancer Network explicitly states that focal therapy is not recommended for high-risk localized cancer outside of a clinical trial.
This doesn’t mean focal therapy is experimental in the sense of being unproven or unsafe. It means the medical community wants head-to-head comparisons with established treatments before endorsing it as a routine first-line option. In practice, many specialized cancer centers offer focal therapy to carefully selected patients, and thousands of men have been treated with it worldwide. The gap is in the type of evidence, not necessarily in the results seen so far.